2. Search Result
Search Result
Results for "

fibril formation

" in MedChemExpress (MCE) Product Catalog:

35

Inhibitors & Agonists

1

Fluorescent Dyes

1

Biochemical Assay Reagents

9

Peptides

1

Inhibitory Antibodies

5

Natural
Products

1

Isotope-Labeled Compounds

3

Oligonucleotides

Cat. No. Nombre del producto Target Áreas de investigación Chemical Structure
  • HY-137131
    DC-Chol hydrochloride

    DC-Cholesterol hydrochloride

    		 Amyloid-β Liposome IFNAR Interleukin Related Neurological Disease Inflammation/Immunology
    DC-Chol hydrochloride is a cationic lipid. DC-Chol hydrochloride could inhibit Aβ40 fibril formation under appropriate experimental conditions. DC-Chol hydrochloride strongly inhibits amyloidogenesis of oxidized hCT in a dose-dependent manner. DC-Chol hydrochloride induces the production of Th1 (IL-2 and IFN-γ) and Th2 (IL-5) cytokines. DC-Chol hydrochloride can enhance the body's immune response to antigens. DC-Chol hydrochloride is used as a gene delivery vector. DC-Chol hydrochloride can be used in research in areas such as hepatitis B vaccines to improve vaccine immunity .
    DC-Chol hydrochloride
  • HY-148089
    Eplontersen
    1 Publications Verification

    		 Transthyretin (TTR) Neurological Disease
    Eplontersen is a triantennary N-acetyl galactosamine (GalNAc3-7a)-conjugated antisense oligonucleotide targeting transthyretin (TTR) mRNA to inhibit production of both variant and wild-type TTR protein. Misfolded TTR induces amyloid fibrils formation in the heart and peripheral nerves, leads to amyloid TTR (ATTR) amyloidosis diseases .
    Eplontersen
  • HY-N7046
    Silybin B

    Silibinin B

    		 Amyloid-β Apoptosis JNK p38 MAPK Neurological Disease Cancer
    Silybin B (Silibinin B) is an orally active amyloid-β aggregation inhibitor and ATR pathway activator that can cross the blood-brain barrier. Silybin B inhibits Aβ fibril formation and promotes amorphous aggregate formation, while activating the ATR-mediated DNA damage repair pathway and inhibiting JNK/p38 MAPK signaling. Silybin B can reduce Cisplatin (HY-17394)-induced neuronal DNA damage and apoptosis. Silybin B has anti-oxidative stress, cell cycle regulation and neuroprotective activities. Silybin B is mainly used in the study of Alzheimer's disease and Cisplatin chemotherapy-related neurotoxicity .
    Silybin B
  • HY-160116
    α-Synuclein aggregate binder 1

    		Radionuclide-Drug Conjugates (RDCs) Fluorescent Dye α-synuclein Neurological Disease
    α-Synuclein aggregate binder 1 (Compound C05-05) is a specific binder for α-synuclein aggregates and can inhibit α-synuclein aggregation. α-Synuclein aggregate binder 1 can be used as a fluorescent probe (excitation wavelength 900 nm, detection wavelength 500-550 nm) for optical imaging, and can also inhibit α-synuclein fibril formation by blocking the aggregation process. α-Synuclein aggregate binder 1 can be used for positron emission tomography (PET) imaging after being labeled with 18F. α-Synuclein aggregate binder 1 can be used for visual diagnosis of brain lesions and mechanism research of neurodegenerative diseases such as Parkinson's disease and Lewy body dementia .
    α-Synuclein aggregate binder 1
  • HY-18257
    Rolitetracycline

    		Antibiotic Bacterial Dengue Virus Amyloid-β HIV Integrase Infection Neurological Disease Inflammation/Immunology
    Rolitetracycline is a highly soluble, broad-spectrum antibiotic derived from tetracycline. Rolitetracycline binds to and stabilizes bovine serum albumin, and also inhibits HIV-1 integrase, blocks Aβ fibril formation and suppresses dengue virus proliferation. Rolitetracycline mediates the inhibition of Aβ fibrils via a specific three-dimensional pharmacophore conformation, and exerts bacteriostatic and bactericidal activities. Rolitetracycline acts synergistically with Penicillin G (HY-N7139) or Cephalothin (HY-B1275A) to alter the effects on microbial growth. Rolitetracycline serves as an important tool compound for the study of bacterial infections (urinary tract infections, sepsis), HIV-1 and dengue virus infections, as well as Alzheimer's disease .
    Rolitetracycline
  • HY-145580
    Minzasolmin

    UCB0599; (R)-NPT200-11

    		 α-synuclein Neurological Disease
    Minzasolmin (UCB0599; (R)-NPT200-11) is an orally active, blood-brain-permeable α-synuclein (α-Syn) inhibitor that selectively binds to α-Syn misfolded intermediates (such as oligomers) and inhibits aggregation and fibril formation by regulating their conformational stability. Minzasolmin can reduce the generation of pathological oligomers and block neurotoxic signaling, thereby reducing the abnormal accumulation of α-Syn in the brain. Minzasolmin significantly improved motor deficits, reduced neuroinflammatory markers, and α-Syn-related pathological deposition in transgenic mouse models .
    Minzasolmin
  • HY-P5124
    β-Amyloid peptide(16-20)

    KLVFF

    		 Amyloid-β Neurological Disease
    β-Amyloid peptide(16-20) is a amino acid sequences (KLVFF) of Amyloid-β (Abeta). β-Amyloid peptide(16-20) is an effective inhibitor of Abeta fibril formation, with RG-/-GR-NH2 residues added at N- and C-terminal ends to aid solubility) .
    β-Amyloid peptide(16-20)
  • HY-148089A
    Eplontersen sodium
    1 Publications Verification

    		 Transthyretin (TTR) Neurological Disease
    Eplontersen sodium the sodium salt form of Eplontersen (HY-148089). Eplontersen sodium is a triantennary N-acetyl galactosamine (GalNAc3-7a)-conjugated antisense oligonucleotide targeting transthyretin (TTR) mRNA to inhibit production of both variant and wild-type TTR protein. Misfolded TTR induces amyloid fibrils formation in the heart and peripheral nerves, leads to amyloid TTR (ATTR) amyloidosis diseases .
    Eplontersen sodium
  • HY-171179
    BD-Oligo

    		Fluorescent Dye Neurological Disease
    BD-Oligo is an oligomer-specific fluorescent chemical probe. BD-Oligo preferentially identifies Aβ oligomer assemblies over monomers or fibrils by using diversity-directed fluorescent library (DOFL) screening and computational techniques. BD-Oligo exhibits dynamic oligomer monitoring capabilities during Aβ peptide fibril formation as Aβ is induced to form oligomers and ultimately fibrils over time. BD-Oligo also exhibits blood-brain barrier permeability with the ability to stain Aβ oligomers in vivo .
    BD-Oligo
  • HY-N0413
    Hupehenine

    		α-synuclein Reactive Oxygen Species (ROS) Apoptosis Autophagy Parasite Infection Neurological Disease Inflammation/Immunology Cancer
    Hupehenine is an orally active isosteroidal alkaloid that can be extracted from F. hupehensis. Hupehenine exhibits activities such as antitussive, expectorant, anticancer, and antiparasitic. In vitro, Hupehenine can also inhibit α-synuclein seeded fibril formation, making it applicable for the research of Parkinson's disease and other related disorders .
    Hupehenine
  • HY-P5082
    α-Synuclein 4554W

    		α-synuclein Neurological Disease
    α-Synuclein 4554W is an inhibitor of α-Synuclein (aSyn) aggregation with associated toxicity. α-Synuclein 4554W consists of GIVNGVKA sequences, previously identified through intracellular library screening. α-Synuclein 4554W reduces fibril formation of aSyn mutants assocaited with Parkinson’s disease .
    α-Synuclein 4554W
  • HY-P4767
    Amylin (1-13) (human)

    		Amylin Receptor Metabolic Disease
    Amylin (1-13) (human) is a fragment and a residues within amyloid cores of Amylin (human IAPP). Amylin is a glucose-regulating hormone, deposits as amyloid fibrils in condition of type II diabetes (T2D). Amylin (1-13) (human) has no effect on firbl formation, as it cannot form fibrils by itself .
    Amylin (1-13) (human)
  • HY-P5905
    Citrullinated amyloid-β (1-42) peptide (human)

    Citrullinated Aβ (1-42); Citrullinated Aβ42

    		 Amyloid-β Neurological Disease
    Citrullinated amyloid-β (1-42) peptide (human) (Citrullinated Aβ (1-42)) is a modified form of β-Amyloid (1-42) (HY-P1363) with a citrullination at the Arg5 site. Compared to the unmodified β-Amyloid (1-42), its formation of soluble low-molecular-weight oligomers is enhanced, the rate of fibril formation is reduced, and like unmodified Aβ42, it forms protofibrils comprised of parallel β-sheets .
    Citrullinated amyloid-β (1-42) peptide (human)
  • HY-103442
    CGP52411
    1 Publications Verification

    DAPH

    		 EGFR Amyloid-β Neurological Disease Cancer
    CGP52411 (DAPH) is a high selective, potent, orally active and ATP-competitive EGFR inhibitor with an IC50 of 0.3 μM. CGP52411 blocks the toxic influx of Ca 2+ ions into neuronal cells, and dramatic inhibits and reverses the formation of β-amyloid (Aβ42) fibril aggregates associated with Alzheimer's disease .
    CGP52411
  • HY-P5681
    Human α-Defensin 6

    		Bacterial Infection Inflammation/Immunology
    Human α-Defensin 6, a 32-residue cysteine-rich peptide, can inhibit bacterial invasion and contribute to the mucosal immunity. Human α-Defensin 6 forms ordered self-assembly fibrils and nanonets that surround and entangle bacteria after stochastic binding to bacterial surface proteins. Human α-Defensin 6 also inhibits C. albicans biofilm formation .
    Human α-Defensin 6
  • HY-115650
    TAE-1

    		Cholinesterase (ChE) Amyloid-β Neurological Disease
    TAE-1 is a potent inhibitor of AChE and BuChE. TAE-1 also inhibits Aβ fibril formation and aggregation. TAE-1 can be used for the researches of Alzheimer's disease .
    TAE-1
  • HY-P4295
    Z-Phe-Ala-diazomethylketone

    PADK

    		 Cathepsin γ-secretase Neurological Disease
    Z-Phe-Ala-diazomethylketone binds directly to Aβ42 monomers and small oligomers. Z-Phe-Ala-diazomethylketone inhibits the formation of Aβ42 dodecamers and inhibits Aβ42 fibril formation in the solution. Z-Phe-Ala-diazomethylketone has the potential for neurodegenerative disorders research .
    Z-Phe-Ala-diazomethylketone
  • HY-149764
    Aβ42 agonist-2

    		Amyloid-β Neurological Disease
    Aβ42 agonist-2 (compound 7b) is a small molecule compound that can promote Aβ42 aggregation. Aβ42 agonist-2 can interact with Aβ42 oligomers and pentamers to promote nontoxic aggregate self-assembly and rapid fibril formation. Aβ42 agonist-2 prevents Aβ42-induced cytotoxicity in HT22 hippocampal neuronal cells .
    Aβ42 agonist-2
  • HY-W265961
    Squoxin

    ST1859; 1,1′-Methylenedi-2-naphthol

    		 Amyloid-β Neurological Disease Inflammation/Immunology
    Squoxin (ST1859) is an antiamyloid agent that specifically binds to Aβ1-42 and prevents the aggregation and fibril formation of Aβ. Squoxin crosses the blood-brain barrier (BBB) and has anthelmintic activity and anti-inflammatory properties .
    Squoxin
  • HY-P10494
    FEFEFKFK

    		Amyloid-β Neurological Disease
    FEFEFKFK is an octapeptide that self-assembles into fibrillar structures. FEFEFKFK is able to form gels at concentrations greater than about 7 mg/mL. The self-assembly and gelation properties of FEFEFKFK help to understand the mechanism of amyloid fibril formation in protein misfolding diseases such as Alzheimer's disease and Parkinson's disease .
    FEFEFKFK
  • HY-146137
    Transthyretin-IN-1

    		Transthyretin (TTR) Neurological Disease
    Transthyretin-IN-1 (Compound 1d) is a transthyretin (TTR) fibril formation inhibitor. Transthyretin-IN-1 can be used for Alzheimer’s disease research .
    Transthyretin-IN-1
  • HY-113950
    Dichlorophenyl-ABA

    		Transthyretin (TTR) Neurological Disease
    Dichlorophenyl-ABA is an inhibitor of transthyretin (TTR) amyloid fibril formation, inhibiting aggregate formation in more than 80% in TTR L55P-expressing cells .
    Dichlorophenyl-ABA
  • HY-157225
    Brazilin-7-acetate

    		α-synuclein Metabolic Disease
    Brazilin-7-acetate (B-7-A) is an inhibitor of α-synuclein (α-Syn) aggregates. Brazilin-7-acetate inhibits the formation of α-synuclein fibril, mitigates cytotoxicity, and decreases oxidative stress. Brazilin-7-acetate can be used in the research of Parkinson's disease .
    Brazilin-7-acetate
  • HY-149582
    Aβ-IN-7

    		Amyloid-β Neurological Disease
    Aβ-IN-7 (compound 5a) is a potent inhibitor of the Aβ aggregation. Aβ-IN-7 with 50 μM stabilize Aβ monomers in the small oligomeric species and prolong the nucleation process. Aβ-IN-7 inhibits Aβ fibril formation better than Aβ-IN-8 (HY-149583) in 50 μM .
    Aβ-IN-7
  • HY-14533
    K 01-162

    K162

    		 Amyloid-β Neurological Disease
    K 01-162 (K162) inhibits the fibril formation of Aβ peptides and eliminates their neurotoxicity. K 01-162 binds with Aβ42 peptide with an EC50 value of 80 nM. K 01-162 binds directly to AβO with a KD value of 19 μM. K 01-162 is capable of penetrating the brain and can be used for the research of Alzheimer’s disease .
    K 01-162
  • HY-N6640
    2-O-Acetyl-20-hydroxyecdysone

    20-Hydroxyeedysone 2-acetate

    		 Amyloid-β Neurological Disease
    2-O-Acetyl-20-hydroxyecdysone, an ecdysterones in insects and terrestrial plants, inhibits amyloid-β42 (Aβ42)-induced cytotoxicity. 2-O-Acetyl-20-hydroxyecdysone could decrease Aβ oligomer formation through promotion of fibrogenesis, transforming Aβ oligomers to the low-toxicity fibrils .
    2-O-Acetyl-20-hydroxyecdysone
  • HY-N0413R
    Hupehenine (Standard)

    		Reference Standards α-synuclein Reactive Oxygen Species (ROS) Apoptosis Autophagy Parasite Infection Neurological Disease Inflammation/Immunology Cancer
    Hupehenine (Standard) is the analytical standard of Hupehenine (HY-N0413). This product is intended for research and analytical applications. Hupehenine is an orally active isosteroidal alkaloid that can be extracted from F. hupehensis. Hupehenine exhibits activities such as antitussive, expectorant, anticancer, and antiparasitic. In vitro, Hupehenine can also inhibit α-synuclein seeded fibril formation, making it applicable for the research of Parkinson's disease and other related disorders .
    Hupehenine (Standard)
  • HY-149763
    Aβ42 agonist-1

    		Amyloid-β Neurological Disease
    Aβ42 agonist-1 is a compound that can promote Aβ42 aggregation. Aβ42 agonist-1 can interact with Aβ42 oligomers and pentamers to promote nontoxic aggregate self-assembly and rapid fibril formation. Aβ42 agonist-1 prevents Aβ42-induced cytotoxicity in HT22 hippocampal neuronal cells .
    Aβ42 agonist-1
  • HY-N7046R
    Silybin B (Standard)

    Silibinin B (Standard)

    		 Reference Standards JNK Amyloid-β p38 MAPK Apoptosis Neurological Disease Cancer
    Silybin (Silibinin B) (Standard) is the analytical standard of Silybin B (HY-N7046). This product is intended for research and analytical applications. Silybin B (Silibinin B) is an orally active amyloid-β aggregation inhibitor and ATR pathway activator, that can cross the blood-brain barrier. Silybin B inhibits Aβ fibril formation and promotes amorphous aggregate formation, while activating the ATR-mediated DNA damage repair pathway and inhibiting JNK/p38 MAPK signaling. Silybin B can reduce Cisplatin (HY-17394)-induced neuronal DNA damage and apoptosis. Silybin B has anti-oxidative stress, cell cycle regulation and neuroprotective activities. Silybin B is mainly used in the study of Alzheimer's disease and Cisplatin chemotherapy-related neurotoxicity .
    Silybin B (Standard)
  • HY-N7046S
    Silybin B-d3

    Silibinin B-d3

    		 Isotope-Labeled Compounds Amyloid-β Apoptosis JNK p38 MAPK Neurological Disease Cancer
    Silybin B-d3 (Silibinin B-d3) is a deuterated Silybin B (HY-N7046). Silybin B (Silibinin B) is an orally active amyloid-β aggregation inhibitor and ATR pathway activator, that can cross the blood-brain barrier. Silybin B inhibits Aβ fibril formation and promotes amorphous aggregate formation, while activating the ATR-mediated DNA damage repair pathway and inhibiting JNK/p38 MAPK signaling. Silybin B can reduce Cisplatin (HY-17394)-induced neuronal DNA damage and apoptosis. Silybin B has anti-oxidative stress, cell cycle regulation and neuroprotective activities. Silybin B is mainly used in the study of Alzheimer's disease and Cisplatin chemotherapy-related neurotoxicity .
    Silybin B-d3
  • HY-181861
    AChE/MAO-B-IN-9

    		Cholinesterase (ChE) Monoamine Oxidase Amyloid-β Tau Protein Neurological Disease
    AChE/MAO-B-IN-9 (Compound E12) is an orally active, selective, reversible, non-competitive AChE and MAO-B inhibitor, with an IC50 of 0.156 μM against electric eel AChE. AChE/MAO-B-IN-9 inhibits Aβ40/42 fibril formation, promotes Aβ fibril depolymerization, and inhibits Tau protein fibril formation. AChE/MAO-B-IN-9 exerts antioxidant and neuroprotective effects, and improves scopolamine (HY-N0296)-induced memory impairment in mice. AChE/MAO-B-IN-9 can be used for the research of Alzheimer's disease .
    AChE/MAO-B-IN-9
  • HY-114613
    D-Trp-Aib

    		Amyloid-β α-synuclein CGRP Receptor Amylin Receptor Neurological Disease Inflammation/Immunology
    D-Trp-Aib is a dipeptide and amyloid-β inhibitor with a Kd of 29.6 nM. D-Trp-Aib triggers formation of non-toxic, non-β-sheet, amorphous amyloid β clusters from misfolded amyloid β monomers and toxic amyloid β oligomers, and reduces toxic amyloid β1-42 deposits. D-Trp-Aib inhibits amyloid fibril formation of α‑synuclein, IAPP and calcitonin. D-Trp-Aib can be used for the research of Alzheimer's disease .
    D-Trp-Aib
  • HY-P991867
    SHR-1707

    		Amyloid-β Neurological Disease
    SHR-1707 is a humanized anti-Aβ IgG1 monoclonal antibody. SHR-1707 binds Aβ fibrils and monomers, blocking plaque formation and promoting the microglial phagocytosis of Aβ. SHR-1707 reduces brain Aβ deposition in 5xFAD transgenic mice. SHR-1707 can be used for Alzheimer’s disease research. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
    SHR-1707
  • HY-103442R
    CGP52411 (Standard)

    DAPH (Standard)

    		 Reference Standards EGFR Amyloid-β Neurological Disease Cancer
    CGP52411 (Standard) is the analytical standard of CGP52411 (HY-103442). This product is intended for research and analytical applications. CGP52411 (DAPH) is a high selective, potent, orally active and ATP-competitive EGFR inhibitor with an IC50 of 0.3 μM. CGP52411 blocks the toxic influx of Ca2+ ions into neuronal cells, and dramatic inhibits and reverses the formation of β-amyloid (Aβ42) fibril aggregates associated with Alzheimer's disease .
    CGP52411 (Standard)
  • HY-116942
    2002-H20

    		Amyloid-β Neurological Disease
    2002-H20 is an inhibitor of Aβ42-induced cytotoxicity, with the activity of reducing the cytotoxicity of Alzheimer's disease Aβ peptide by binding to it. 2002-H20 protects cells and reduces Aβ toxicity by promoting fibril formation, possibly by accelerating Aβ aggregation. The screening method of 2002-H20 effectively identifies compounds that reduce Aβ toxicity and presents potential inhibitory leads .
    2002-H20

Consulta en línea

Your information is safe with us. * Required Fields.

Saludo

  

Country or Region *

Nombre del solicitante *

 

Nombre de la Organizaciòn *

Department *

     

Direcciòn del E-mail *

 

Nombre del producto *

Cat. No.

  

Requested quantity *

Número de teléfono *

     

Observaciones

Consulta en línea

Inquiry Information

Nombre del producto:
Cat. No.:
Cantidad:
MCE Japan Authorized Agent: